[PDF][PDF] Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss

…, SR Rajapurkar, S O'Brien, SV Gerhart, LH Mitchell… - Cancer cell, 2019 - cell.com
Type I protein arginine methyltransferases (PRMTs) catalyze asymmetric dimethylation of
arginines on proteins. Type I PRMTs and their substrates have been implicated in human …

Aryl pyrazoles as potent inhibitors of arginine methyltransferases: identification of the first PRMT6 tool compound

LH Mitchell, AE Drew, SA Ribich, N Rioux… - ACS medicinal …, 2015 - ACS Publications
A novel aryl pyrazole series of arginine methyltransferase inhibitors has been identified.
Synthesis of analogues within this series yielded the first potent, selective, small molecule …

4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Inhibitors of the Checkpoint Kinase Wee1. Structure−Activity Relationships for Chromophore Modification and …

…, HH Lee, EA Lunney, LH Mitchell… - Journal of medicinal …, 2006 - ACS Publications
High-throughput screening has identified a novel class of inhibitors of the checkpoint kinase
Wee1, which have potential for use in cancer chemotherapy. These inhibitors are based on …

[HTML][HTML] Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

…, T Riera, G Shapiro, NJ Waters, LH Mitchell… - Scientific reports, 2017 - nature.com
CARM1 is an arginine methyltransferase with diverse histone and non-histone substrates
implicated in the regulation of cellular processes including transcriptional co-activation and …

Novel oxindole sulfonamides and sulfamides: EPZ031686, the first orally bioavailable small molecule SMYD3 inhibitor

LH Mitchell, PA Boriack-Sjodin, S Smith… - ACS medicinal …, 2016 - ACS Publications
SMYD3 has been implicated in a range of cancers; however, until now no potent selective
small molecule inhibitors have been available for target validation studies. A novel oxindole …

[HTML][HTML] Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell …

MJ Thomenius, J Totman, D Harvey, LH Mitchell… - PLoS …, 2018 - journals.plos.org
A key challenge in the development of precision medicine is defining the phenotypic
consequences of pharmacological modulation of specific target macromolecules. To address this …

On the minimum rank among positive semidefinite matrices with a given graph

…, B Harris, CR Johnson, M Lay, LH Mitchell… - SIAM Journal on Matrix …, 2008 - SIAM
Let $\mathcal{P}(G)$ be the set of all positive semidefinite matrices whose graph is G, and $\operatorname{msr}(G)$
be the minimum rank of all matrices in $\mathcal{P}(G)$. Upper and …

Commitment to germ tube or bud formation during release from stationary phase in Candida albicans

LH Mitchell, DR Soll - Experimental Cell Research, 1979 - Elsevier
Cells of the pathogenic yeast Candida albicans accumulate as unbudded singlets at stationary
phase in defined medium at 25 C. When released into fresh medium at 37 C and pH 6.5, …

Linearly independent vertices and minimum semidefinite rank

P Hackney, B Harris, M Lay, LH Mitchell… - Linear Algebra and its …, 2009 - Elsevier
We study the minimum semidefinite rank of a graph using vector representations of the
graph and of certain subgraphs. We present a sufficient condition for when the vectors …

An enantioselective total synthesis of (+)-and (−)-saudin. Determination of the absolute configuration

…, M del Rosario Rico Ferreira, LH Mitchell… - Journal of the …, 2002 - ACS Publications
A short efficient enantioselective synthesis of both (+)- and (−)-saudin, a naturally occurring
hypoglycemic diterpene, is described. This synthesis establishes the absolute configuration …